Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ

被引:5
|
作者
Tomasicchio, Giovanni [1 ]
Picciariello, Arcangelo [1 ]
Stucci, Luigia S. [2 ]
Panebianco, Annunziata [3 ]
Montanaro, Alda E. [4 ]
Cirilli, Alfredo [4 ]
Punzo, Clelia [1 ]
机构
[1] Univ Bari, Aldo Moro Univ, M Rubino Unit Gen Surg, Div Surg,Dept Emergency & Organ Transplant DETO, Piazza Giulio Cesare 11, I-70124 Bari, Italy
[2] Hosp Bari, Unit Med Oncol, Bari, Italy
[3] Univ Bari, Aldo Moro Univ, Chirurg VideoLaparoscop & Urgenza Unit Gen Surg, Div Surg,Dept Emergency & Organ Transplant DETO, Bari, Italy
[4] Hosp Bari, Unit Breast Surg, Bari, Italy
来源
MINERVA SURGERY | 2022年 / 77卷 / 06期
关键词
Carcinoma; intraductal; noninfiltrating; Breast neoplasms; Aftercare; Prognosis; NUYS PROGNOSTIC INDEX; CLASSIFICATION; MARKERS; CANCER; WOMEN;
D O I
10.23736/S2724-5691.22.09284-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Ductal carcinoma in situ (DCIS) is a tumor with long term survival and low local recurrence rate. Al-though the progression of these lesions is rare, the current guidelines recommend breast conservating surgery (BCS) with adjuvant radio and/or endocrine therapy, often resulting in an overtreatment for patients. The aim of this single-center study was to evaluate the long-term outcome of the breast conservating surgery of DCIS followed by adjuvant radio and/ or endocrine therapy and to identify prognostic factors associated with the risk of recurrence. METHODS: Patients treated for DCIS with BCS and radiation therapy between March 2006 and January 2019 were retrospectively reviewed using a prospectively maintained database. Analysis of the potential risk factors was performed to evaluate the risk of subsequent ipsilateral and contralateral recurrence. RESULTS: Out of 2894 patients, two hundred eighty-eight (10%) patients were treated for DCIS. After a median follow-up of 85 months (IQR 27-124), the incidence of recurrence was 6% (18 patients). Nine of them (3%) had an ipsilateral local recurrence (LR) with a median disease-free survival of 19 months (IQR 12-35). The remaining nine patients had contralateral metachronous breast cancer (CBC) with a median DFS of 29 months (IQR 14-36). Margin status, multifo-cality, hormone receptor status and Her-2/Basal-like subtype were identified as risk factors for the local recurrence with a OR of 5.58 (1.44-21.54), 7.46(1.89-24.48) 0.25 (0.06-0.96) and 4.86 (1.26-18.71) respectively. CONCLUSIONS: DCIS had been confirmed to have long term survival. Margin status, multifocality, hormone receptor status and Her-2/Basal-like subtype could be identified as reliable risk factors for the progression of the disease.
引用
收藏
页码:536 / 541
页数:6
相关论文
共 50 条
  • [21] Impact of Race and Ethnicity on Recurrence Risk in Patients with Ductal Carcinoma in Situ Treated with Breast-Conserving Surgery
    Polidorio, Natalia
    Jones, V. Morgan
    Sevilimedu, Varadan
    Morrow, Monica
    Van Zee, Kimberly
    Barrio, Andrea
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Validation of a Nomogram in the Prediction of Local Recurrence Risks after Conserving Surgery for Asian Women with Ductal Carcinoma in Situ of the Breast
    Wang, F.
    Li, H.
    Tan, P. H.
    Chua, E. T.
    Yeo, R. M. C.
    Lim, F. L. W. T.
    Kim, S. W.
    Tan, D. Y. H.
    Wong, F. Y.
    CLINICAL ONCOLOGY, 2014, 26 (11) : 684 - 691
  • [23] Nomogram for Risk of Relapse After Breast-Conserving Surgery in Ductal Carcinoma In Situ
    Mazouni, Chafika
    Delaloge, Suzette
    Rimareix, Francoise
    Garbay, Jean-Remi
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (02) : E44 - E44
  • [24] Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?
    Kim, Taeryung
    Park, Heung Kyu
    Lee, Kyung Hee
    Kim, Kwan Il
    Lee, Kyu Chan
    Ahn, Jeong Suk
    Ko, Kwang-Pil
    SPRINGERPLUS, 2015, 3 : 1 - 9
  • [25] Risk of recurrence after ductal carcinoma in situ of the breast
    Habel, LA
    Daling, JR
    Newcomb, PA
    Self, SG
    Porter, PL
    Stanford, JL
    Seidel, K
    Weiss, NS
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1998, 7 (08) : 689 - 696
  • [26] Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery
    Punglia, Rinaa S.
    Jiang, Wei
    Lipsitz, Stuart R.
    Hughes, Melissa E.
    Schnitt, Stuart J.
    Hassett, Michael J.
    Nekhlyudov, Larissa
    Achacoso, Ninah
    Edge, Stephen
    Javid, Sara H.
    Niland, Joyce C.
    Theriault, Richard L.
    Wong, Yu-Ning
    Habel, Laurel A.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 751 - 759
  • [27] Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery
    Rinaa S. Punglia
    Wei Jiang
    Stuart R. Lipsitz
    Melissa E. Hughes
    Stuart J. Schnitt
    Michael J. Hassett
    Larissa Nekhlyudov
    Ninah Achacoso
    Stephen Edge
    Sara H. Javid
    Joyce C. Niland
    Richard L. Theriault
    Yu-Ning Wong
    Laurel A. Habel
    Breast Cancer Research and Treatment, 2018, 167 : 751 - 759
  • [28] Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy
    Weinmann, Sheila
    Leo, Michael C.
    Francisco, Melanie
    Jenkins, Charisma L.
    Barry, Todd
    Leesman, Glen
    Linke, Steven P.
    Whitworth, Pat W.
    Patel, Rakesh
    Pellicane, James
    Warnberg, Fredrik
    Bremer, Troy
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4054 - 4063
  • [29] Molecular Expression Assays Improve the Prediction of Local and Invasive Local Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ
    Hahn, Ezra
    Sutradhar, Rinku
    Paszat, Lawrence
    Nguyen, Lena
    Rodin, Danielle
    Nofech-Mozes, Sharon
    Trebinjac, Sabina
    Jerzak, Katarzyna J.
    Fong, Cindy
    Rakovitch, Eileen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (27)
  • [30] Factors associated with local recurrence of mammographically detected ductal carcinoma in situ in patients given breast-conserving therapy
    Kestin, LL
    Goldstein, NS
    Lacerna, MD
    Balasubramaniam, M
    Martinez, AA
    Rebner, M
    Pettinga, J
    Frazier, RC
    Vicini, FA
    CANCER, 2000, 88 (03) : 596 - 607